Yvonne M Saenger (Yvonne Saenger)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 9

Top Topics

Randomized Controlled Trial

Pluripotent Stem Cells

Top Venues

Cancer research communications

Journal of hepatocellular carcinoma

Cancer immunology, immunotherapy : CII

American journal of clinical dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

Fernand Bteich, Kush Desai, Chenxin Zhang, Anahat Kaur, Rachel A Levy, Lydia Bioh, Aaron Wang, Sharmin Sultana, Andreas Kaubisch, Milan Kinkhabwala, Sarah Bellemare, Shabnam Fidvi, Devaraju Kanmaniraja, Robert Berkenblit, Jee-Young Moon, Adebola Adedimeji, Clara Y Tow, Yvonne M Saenger
Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma in a Diverse and Underserved Population in the United States. Journal of hepatocellular carcinoma 11 (2024)
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications 4 (4) (2024)
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications 4 (4) (2024)
Fernand Bteich, Kush Desai, Chenxin Zhang, Anahat Kaur, Rachel A Levy, Lydia Bioh, Aaron Wang, Sharmin Sultana, Andreas Kaubisch, Milan Kinkhabwala, Sarah Bellemare, Shabnam Fidvi, Devaraju Kanmaniraja, Robert Berkenblit, Jee-Young Moon, Adebola Adedimeji, Clara Y Tow, Yvonne M Saenger
Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma in a Diverse and Underserved Population in the United States. Journal of hepatocellular carcinoma 11 (2024)
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-Human Phase I Trial of TPST-1120, an inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications (2024)
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications 4 (4) (2024)
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications 4 (4) (2024)
Robyn D Gartrell, Zoë Blake, Emanuelle M Rizk, Rolando Perez-Lorenzo, Stuart P Weisberg, Ines Simoes, Camden Esancy, Yichun Fu, Danielle R Davari, Luke Barker, Grace Finkel, Manas Mondal, Hanna E Minns, Samuel W Wang, Benjamin T Fullerton, Francisco Lozano, Codruta Chiuzan, Basil Horst, Yvonne M Saenger
Combination immunotherapy including OncoVEX mGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma. Cancer immunology, immunotherapy : CII 71 (8) (2022)
Emanuelle M Rizk, Angelina M Seffens, Megan H Trager, Michael R Moore, Larisa J Geskin, Robyn D Gartrell-Corrado, Winston Wong, Yvonne M Saenger
Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma. American journal of clinical dermatology 21 (1) (2020)